Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomic Analysis Reveals an IFN-driven Cellular Landscape Effectively Targeted by Ruxolitinib in Hailey-Hailey Disease.

bioRxiv : the preprint server for biology·2026
Same author

CARMN fusions and PDGFRB mutations highlight key differences among cutaneous tumors with myopericytic differentiation.

The Journal of investigative dermatology·2026
Same author

Updates in Skin Adnexal Tumors.

Dermatologic clinics·2026
Same author

Single-cell and spatial profiling reveal cDC2A-CXCL13<sup>+</sup>CD8<sup>+</sup> T-epithelial cell crosstalk and cytotoxicity through TNFRSF9 in cutaneous and mucosal lichen planus.

Nature communications·2026
Same author

Spatially controlled induction and regression of basal cell carcinoma, visualized by serial imaging in young and old mice.

JID innovations : skin science from molecules to population health·2026
Same author

Human papilloma virus infection and mismatch repair protein expression in sebaceous neoplasms of the genital area.

Histopathology·2025
Same journal

Blastic Plasmacytoid Dendritic Cell Neoplasm.

Journal of cutaneous pathology·2026
Same journal

Atypical Grover Disease Associated With Merkel Cell Carcinoma: A Novel Paraneoplastic Presentation.

Journal of cutaneous pathology·2026
Same journal

Profile of a Founder: Herbert Zachareus Lund.

Journal of cutaneous pathology·2026
Same journal

The National Resident Match Program Arrives in Dermatopathology: 15 Years of Resilient Advocacy by the American Society of Dermatopathology's Fellowship Training Program Directors' Committee.

Journal of cutaneous pathology·2026
Same journal

Evaluating Large Language Models for Melanocytic Lesion Pathology Report Interpretation.

Journal of cutaneous pathology·2026
Same journal

An Atypical Skin Presentation of Adult-Onset Still's Disease With Histological Description: A Case Report.

Journal of cutaneous pathology·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

CD163 expression in leukemia cutis.

Paul W Harms1, Bizhan Bandarchi, Linglei Ma

  • 1Department of Pathology, University of Michigan Medical Center, Ann Arbor, MI 48109-0602, USA.

Journal of Cutaneous Pathology
|February 24, 2010
PubMed
Summary
This summary is machine-generated.

CD163 is a specific marker for myeloid leukemia cutis (LC) with a monocytic component, showing 90% specificity. However, its low sensitivity means CD163 should complement, not replace, existing diagnostic markers for myeloid LC.

More Related Videos

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Related Experiment Videos

Last Updated: Jun 16, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Area of Science:

  • Hematology
  • Dermatology
  • Immunohistochemistry

Background:

  • Accurate diagnosis of myeloid leukemia cutis (LC) is clinically crucial but challenging due to the lack of a single, highly sensitive and specific immunohistochemical marker.
  • A comprehensive panel of markers is often necessary for definitive LC diagnosis.
  • CD163, a marker specific to the monocyte/histiocyte lineage, was investigated for its diagnostic utility in acute myeloid LC.

Purpose of the Study:

  • To evaluate the diagnostic value of CD163 in acute myeloid leukemia cutis (LC).
  • To determine the sensitivity and specificity of CD163 for myeloid LC, particularly LC with a monocytic component.

Main Methods:

  • Retrospective analysis of 34 cases of leukemia cutis.
  • Cases included myelomonocytic or monocytic LC (18), myeloid LC without monocytic component (10), and acute lymphoblastic leukemia/lymphoma (ALL) (6).
  • Immunohistochemical staining for CD163 was performed on all cases.

Main Results:

  • CD163 expression was observed in 44% of monocytic LC and 10% of other myeloid LC.
  • CD163 demonstrated high specificity (90%) for myeloid LC with a monocytic component.
  • Sensitivity for myeloid LC in general was low (24%), and for LC with a monocytic component was 44%.

Conclusions:

  • CD163 is a valuable, specific marker for myeloid LC, especially when a monocytic component is present.
  • CD163 should be used in conjunction with other immunohistochemical stains.
  • CD163 alone is insufficient for the definitive diagnosis of myeloid LC.